Search
Now showing items 1-10 of 34
Targeting the RAF/MEK/ERK, PI3K/AKT and P53 pathways in hematopoietic drug resistance
(East Carolina University, 2007)
Roles of the RAF/MEK/ERK Pathway in Cell Growth, Malignant Transformation and Drug Resistance
(East Carolina University, 2007-08)
Growth factors and mitogens use the Ras/Raf/MEK/ERK signaling cascade to transmit signals from their receptors to regulate gene expression and prevent apoptosis. Some components of these pathways are mutated or aberrantly ...
Targeting the leukemic stem cell: the Holy Grail of leukemia therapy
(East Carolina University, 2009-01)
Since the discovery of leukemic stem cells (LSCs) over a decade ago, many of their critical biological
properties have been elucidated, including their distinct replicative properties, cell surface
phenotypes, their ...
Proapoptotic Activity and Chemosensitizing Effect of the Novel Akt Inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-Cell Acute Lymphoblastic Leukemia
(East Carolina University, 2008-09)
Constitutively activated AKT kinase is a common feature of T-cell acute lymphoblastic leukemia (T-ALL). Here, we report that the novel AKT inhibitor (2S)-1-(1H-indol-3-yl)-3-[5-(3-methyl-2Hindazol-5-yl)pyridin-3-yl]oxypr ...
PKR Regulates B56 alpha-mediated BCL2 Phosphatase Activity in Acute Lymphoblastic Leukemia-derived REH Cells
(East Carolina University, 2009-12-19)
Protein phosphatase 2A (PP2A) is a heterotrimer comprising catalytic, scaffold, and regulatory (B) subunits. There are at least 21 B subunit family members. Thus PP2A is actually a family of enzymes defined by which B ...
Targeting prostate cancer based on signal transduction and cell cycle pathways
(East Carolina University, 2008-06-15)
Prostate cancer remains a leading cause of death in men despite increased capacity to diagnose at earlier stages. After prostate cancer has become hormone independent, which often occurs after hormonal ablation therapies, ...
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia
(2012-12)
Signaling through the phosphatidylinositol 3-kinase (PI3K) pathway and its downstream effectors, Akt and mechanistic target of rapamycin (mTOR), is aberrantly activated in acute myeloid leukemia (AML) patients, where it ...
The AKT Inhibitor MK-2206 is Cytotoxic in Hepatocarcinoma Cells Displaying Hyperphosphorylated AKT-1 and Synergizes with Conventional Chemotherapy
(2013-09)
Hepatocellular carcinoma (HCC) is one of the most common potentially lethal human malignancies worldwide. Advanced or recurrent HCC is frequently resistant to conventional chemotherapeutic agents and radiation. Therefore, ...
Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention
(2014-01)
Glycogen synthase kinase-3 (GSK-3) is well documented to participate in a complex array of critical cellular processes. It was initially identified in rat skeletal muscle as a serine/threonine kinase that phosphorylated ...